Biopharma & Life Sciences
Protagonist Therapeutics Executive Compensation (FY25)
PTGX · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 18, 2026
159 figures on this page: 154 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Dinesh Patel, President and Chief Executive Officer, received $12,871,506 in total compensation for fiscal 2025, and compared with the $9,473,819 reported for fiscal 2024, Patel's total was 35.9% higher. For fiscal 2025, the say-on-pay proposal drew 94.4% support at the meeting held June 18, 2026. The disclosed peer group names Agios Pharmaceuticals, Inc., Akero Therapeutics, Inc., Arcellx, Inc., Biohaven, Ltd. and Celldex Therapeutics, Inc., among others. For fiscal 2025, the company reported 3 named executive officers.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Dinesh Patel: $9,473,819 → $12,871,506 (35.9% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Protagonist Therapeutics' chief executive and what were they paid?
Dinesh Patel, President and Chief Executive Officer, received $12,871,506 in total compensation for fiscal 2025. Compared with the $9,473,819 reported for fiscal 2024, Patel's total was 35.9% higher.
What was Protagonist Therapeutics' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 94.4% support at the meeting held June 18, 2026.
Which companies are in Protagonist Therapeutics' peer group?
The disclosed peer group names Agios Pharmaceuticals, Inc., Akero Therapeutics, Inc., Arcellx, Inc., Biohaven, Ltd. and Celldex Therapeutics, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Dinesh Patel President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Asif Ali EVP, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Dinesh Patel President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Arturo Molina Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Asif Ali EVP, Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Dinesh Patel President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Arturo Molina Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Asif Ali Executive Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Arturo Molina | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Arturo Molina | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Asif Ali | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Asif Ali | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Dinesh V. Patel | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Dinesh V. Patel | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Dinesh Patel | Option | ◇ | — | ◇ | 01/01/2035 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 02/14/2032 | |
| Option | ◇ | — | ◇ | 01/01/2034 | |
| Option | ◇ | — | ◇ | 01/15/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Asif Ali | Option | ◇ | — | ◇ | 04/17/2032 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 01/01/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 01/01/2035 | |
| Option | ◇ | — | ◇ | 01/15/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Arturo Molina | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 01/01/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/14/2032 | |
| Option | ◇ | — | ◇ | 01/01/2034 | |
| Option | ◇ | — | ◇ | 01/15/2033 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Sarah A. O'Dowd | ◇ | ◇ | ◇ | — | — | — | ◇ |
Bryan Giraudo | ◇ | ◇ | ◇ | — | — | — | ◇ |
Lewis T. Williams, M.D., Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
William D. Waddill | ◇ | ◇ | ◇ | — | — | — | ◇ |
Harold E. Selick, Ph.D Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Dinesh V. Patel, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Agios Pharmaceuticals, Inc. AGIO
- Akero Therapeutics, Inc. AKRO
- Arcellx, Inc. ACLX
- Biohaven, Ltd. BHVN
- Celldex Therapeutics, Inc. CLDX
- Crinetics Pharmaceuticals, Inc. CRNX
- Cytokinetics, Inc. CYTK
- Denali Therapeutics, Inc. DNLI
- Disc Medicine, Inc. IRON
- Geron Corporation GERN
- IDEAYA Biosciences, Inc. IDYA
- Immunovant, Inc. IMVT
- Keros Therapeutics, Inc. KROS
- Kura Oncology, Inc. KURA
- Nurix Therapeutics, Inc. NRIX
- Rhythm Pharmaceuticals, Inc. RYTM
- Structure Therapeutics, Inc. GPCR
- Syndax Pharmaceuticals, Inc. SNDX
- Viking Therapeutics, Inc. VKTX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 18, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 26, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 26, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 25, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 26, 2022 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Protagonist Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Protagonist Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
159 figures on this page: 154 cited to the filing that reported them, 5 calculated from figures it prints.
154 cited to the filing
5 calculated from the filing
Documents cited
- 0001104659-26-075777
- 0001104659-26-0504292025 GRANTS OF PLAN-BASED AWARDS TABLE · 2025 Summary Compensation Table · DIRECTOR COMPENSATION · NON-EMPLOYEE DIRECTOR COMPENSATION FOR FISCAL 2025 · and 1 more section
- 0001104659-25-063038
- 0001104659-25-041206Summary Compensation Table
- 0001104659-24-075162
- 0001104659-24-052999Summary Compensation Table
- 0001104659-23-066057
- 0001104659-22-067589
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Protagonist Therapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/PTGX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Protagonist Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Protagonist Therapeutics discloses
The companies named in PTGX's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}